Samuele Takeshita: Scientific and Practical Aspects of Gene Therapy Access in Hemophilia and SCD
Samuele Takeshita, Head of Sales and Business Development at ELIXI International, shared a post on LinkedIn:
“A highly suggested reading to capture both the scientific and practical aspects of gene therapy access in hemophilia and sickle cell disease (SCD).
It explains how gene therapy science differs between viral vector‑based and ex vivo cell‑based approaches and their clinical implications.
In hemophilia, adeno‑associated viral (AAV) vectors deliver functional factor VIII or IX genes but can trigger inflammatory hepatotoxicity, requiring corticosteroid management.
In SCD, autologous hematopoietic stem cells are modified ex vivo (via lentiviral or CRISPR techniques) and reinfused after conditioning, providing durable functional hemoglobin but high acute toxicity risk.
Both approaches demonstrate durable efficacy, though long‑term safety data remain limited.”
Stay updated with Hemostasis Today.
-
Jul 11, 2026, 11:31Acute DVT Management and the Role of Interventions Beyond Anticoagulation: Insights From ISTH 2026
-
Jul 11, 2026, 09:48International Collaboration in Antithrombotic Stewardship – Anticoagulation Forum
-
Jul 11, 2026, 09:45Presenting New CRP-A Data at ISTH 2026 – Pplus Medical Limited
-
Jul 11, 2026, 09:41David Smadja: Addressing the Hidden Threat of Medical Misinformation at ISTH 2026
-
Jul 11, 2026, 09:40Dianne E. van der Wal: The Latest Advances in Hemostasis and Thrombosis on First Day of ISTH 2026
-
Jul 11, 2026, 09:34Heading to ISTH 2026 in Paris Join our session on patient led VTE education – NBCA
-
Jul 11, 2026, 09:33Flora Peyvandi: Empowering the Next Generation of ISTH
-
Jul 11, 2026, 09:28Ruah Alyamany: Surgical and Procedural Bleeding Risk – Perioperative AC guidance
-
Jul 11, 2026, 09:24Habib Bennaceur: New Perspectives on Patient-Centered Hemophilia Care at ISTH 2026